








































































































































































































































































































































































































































































































































































































Heart	function	 13	 4.5				 (2.8-5.0)	
Renal	function	 7	 2.0							 (2.0-	3.5)	

















































































































































































































































































































































































































































































	 ↑ATP/pCR	ratio	 √	 2	 N.A	















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































# Searches Results Search Type 
1 xanthine oxidase.ab,hw,kf,ti,nm. 11112 Advanced 
2 xanthine dehydrogenase.ab,hw,kf,ti,nm. 1518 Advanced 
3 allopurinol.ab,hw,kf,ti,nm. 9031 Advanced 
4 ox?purinol.ab,hw,kf,ti,nm. 652 Advanced 
5 febuxostat.ab,hw,kf,ti,nm. 368 Advanced 
6 "xanthine oxidase inhibitor*".ab,hw,kf,ti,nm. 916 Advanced 
7 exp Xanthine Oxidase/ 6794 Advanced 
8 exp Xanthine Dehydrogenase/ 1033 Advanced 
9 exp Allopurinol/ 6864 Advanced 
10 exp Oxypurinol/ 408 Advanced 
11 CKD.ab,hw,kf,ti,nm. 15042 Advanced 
12 Chronic kidney disease*.ab,hw,kf,ti,nm. 25292 Advanced 
13 Heart failure.ab,hw,kf,ti,nm. 150863 Advanced 
14 CHF.ab,hw,kf,ti,nm. 11230 Advanced 
15 LVEF.ab,hw,kf,ti,nm. 8530 Advanced 
16 "Endothel*".ab,hw,kf,ti,nm. 322718 Advanced 
17 Vasodilation.ab,hw,kf,ti,nm. 39852 Advanced 
18 Creatinine clearance.ab,hw,kf,ti,nm. 16006 Advanced 
19 renal function.ab,hw,kf,ti,nm. 64833 Advanced 
20 kidney function.ab,hw,kf,ti,nm. 33445 Advanced 
21 hypertension.ab,hw,kf,ti,nm. 396177 Advanced 
22 mortality.ab,hw,kf,ti,nm. 557807 Advanced 
23 death.ab,hw,kf,ti,nm. 597745 Advanced 
24 morbidity.ab,hw,kf,ti,nm. 280779 Advanced 
25 cardiac failure.ab,hw,kf,ti,nm. 10538 Advanced 
26 "blood pressure".ab,hw,kf,ti,nm. 382539 Advanced 
27 exp Cardiovascular System/ 1063055 Advanced 
28 exp Cardiovascular Diseases/ 1985701 Advanced 
29 exp Cardiovascular Physiological Phenomena/ 830059 Advanced 
30 exp Kidney/ 311567 Advanced 
31 exp Kidney Diseases/ 436422 Advanced 
32 exp Kidney Failure, Chronic/ 82937 Advanced 
33 exp Heart Failure/ 93302 Advanced 
34 exp Ventricular Dysfunction/ 28584 Advanced 
35 exp Clinical Trial/ 837943 Advanced 
36 exp Comparative Study/ 1733132 Advanced 
37 *Uric Acid/ai, bl, ph [Antagonists & Inhibitors, 
Blood, Physiology] 
4992 Advanced 
38 *Hyperuricemia/bl, mo, pa, pp, th [Blood, 
Mortality, Pathology, Physiopathology, Therapy] 
252 Advanced 
39 exp humans/ 14300939 Advanced 




41 or/11-34 4463296 Advanced 
42 35 and 39 and 40 and 41 303 Advanced 
43 37 or 38 or 40 23546 Advanced 
44 35 and 39 and 41 and 43 480 Advanced 







# Searches Results Search Type 
1 exp cardiovascular system/ 1678863 Advanced 
2 exp cardiovascular disease/ 3453261 Advanced 
3 exp cardiovascular function/ 1484194 Advanced 
4 exp kidney disease/ 780519 Advanced 
5 exp kidney function/ 192842 Advanced 
6 exp kidney/ 439450 Advanced 
7 CKD.ti,ot,hw,ab,dv,kw. 24302 Advanced 
8 "Chronic kidney disease*".ti,ot,hw,ab,dv,kw. 51532 Advanced 
9 Heart failure.ti,ot,hw,ab,dv,kw. 286108 Advanced 
10 CHF.ti,ot,hw,ab,dv,kw. 19458 Advanced 
11 LVEF.ti,ot,hw,ab,dv,kw. 22608 Advanced 
12 "Endothel*".ti,ot,hw,ab,dv,kw. 422211 Advanced 
13 FMD.ti,ot,hw,ab,dv,kw. 8373 Advanced 
14 Flow mediated vasodilation.ti,ot,hw,ab,dv,kw. 1237 Advanced 
15 Vasodilation.ti,ot,hw,ab,dv,kw. 26460 Advanced 
16 clearance.ti,ot,hw,ab,dv,kw. 219849 Advanced 
17 renal function.ti,ot,hw,ab,dv,kw. 97769 Advanced 
18 renal clearance.ti,ot,hw,ab,dv,kw. 8388 Advanced 
19 Glomerular filtration.ti,ot,hw,ab,dv,kw. 48357 Advanced 
20 GFR.ti,ot,hw,ab,dv,kw. 26977 Advanced 
21 kidney function.ti,ot,hw,ab,dv,kw. 123077 Advanced 
22 mortality.ti,ot,hw,ab,dv,kw. 1037384 Advanced 
23 death.ti,ot,hw,ab,dv,kw. 901214 Advanced 
24 morbidity.ti,ot,hw,ab,dv,kw. 466717 Advanced 
25 cardiac failure.ti,ot,hw,ab,dv,kw. 17039 Advanced 
26 myocardial infarction.ti,ot,hw,ab,dv,kw. 218887 Advanced 
27 MI.ti,ot,hw,ab,dv,kw. 58413 Advanced 
28 blood pressure.ti,ot,hw,ab,dv,kw. 509489 Advanced 
29 "hypertens*".ti,ot,hw,ab,dv,kw. 731635 Advanced 
30 exp mortality/ 782118 Advanced 
31 exp death/ 588182 Advanced 
32 exp morbidity/ 266847 Advanced 
33 xanthine oxidase.ti,ot,hw,ab,dv,kw. 14705 Advanced 




35 allopurinol.ti,ot,hw,ab,dv,kw. 20170 Advanced 
36 "ox?purinol.".ti,ot,hw,ab,dv,kw. 1206 Advanced 
37 febuxostat.ti,ot,hw,ab,dv,kw. 1041 Advanced 
38 "xanthine oxidase inhibitor* ".ti,ot,hw,ab,dv,kw. 1867 Advanced 
39 exp febuxostat/ 995 Advanced 
40 exp oxipurinol/ 1079 Advanced 
41 exp allopurinol/ 19223 Advanced 
42 exp xanthine oxidase/ 10929 Advanced 
43 exp xanthine dehydrogenase/ 1296 Advanced 
44 exp xanthine oxidase inhibitor/ 20664 Advanced 
45 human/ 16258236 Advanced 
46 exp controlled clinical trial/ or exp clinical trial/ 
or exp controlled study/ or exp randomized 
controlled trial/ 
5386520 Advanced 
47 or/1-32 7017120 Advanced 
48 or/33-44 33330 Advanced 
49 45 and 46 and 47 and 48 2716 Advanced 
50 limit 49 to english language 2616 Advanced 
51 limit 50 to (clinical trial or randomized controlled 
trial or controlled clinical trial or multicenter study 
or phase 1 clinical trial or phase 2 clinical trial or 
phase 3 clinical trial or phase 4 clinical trial) 
1369 Advanced 










































Hosoya,	T(65)	 2014	 Study	protocol	 Study	protocol	on	future	
study	
Givertz,	M(121)	 2013	 Study	protocol	 Study	protocol	of	included	
study	
White,	W(68)	 2012	 Study	protocol	 Study	protocol	on	future	
study	
Freudenberg,	R.S(67)	 2004	 Study	protocol	 Study	protocol	of	included	
study	
Tausche,	A-K(69)	 2014	 Population	 Tophaceous	gout	patients	
Whelton,	A(71)	 2013	 Population	 Gout	patients	
Whelton,	A(70)	 2011	 Population	 Gout	patients	
Gibson,T(72)	 1982	 Population	 Population	with	gout	
Gibson,	T(142)	 1980	 Population	 Population	with	gout	
Ogino,	K(75)	 2010	 Intervention	 Use	of	Benzobromarone	as	
intervention	
Pop-Busui(74)	 2013	 Intervention	 Three	drugs	vs	placebo	
Kostka-Jeziorny,	K(76)	 2011	 Design		 Not	an	RCT-design	
Terawaki,	H(77)	 2013	 Design	 Non-randomised	kohort	study	
Wei,	L(78)	 2009	 Design	 Cohort	study	
Miranda,	ME(79)	 1994	 Design	 Case-study	
Klinenberg,	J(80)	 1975	 Design	 No	intervention	
Ghosh,	S(81)	 2013	 Animal	study	 Study	on	rats	
Badkoobeh,	R.S(82)	 2011	 Language	 Not	available	in	english	
Shelmadine, B(64)	 2009	 Not	available	 No	full	text	available	
An	overview	of	the	records	that	were	excluded	after	the	initial	screening	of	titles	and	abstract.	The	
records	are	categorized	after	six	reasons	for	exclusion	and	a	further	comment	is	given	on	the	specific	
reason	the	record	was	excluded.	
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